Arena Pharmaceuticals, Inc. (ARNA)
| Market Cap | 3.67B |
| Revenue (ttm) | 57,000 |
| Net Income (ttm) | -484.11M |
| Shares Out | 60.79M |
| EPS (ttm) | -8.18 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 393,873 |
| Open | 60.72 |
| Previous Close | 61.08 |
| Day's Range | 59.55 - 61.31 |
| 52-Week Range | 45.50 - 90.19 |
| Beta | 0.49 |
| Analysts | Strong Buy |
| Price Target | 95.25 (+58.5%) |
| Est. Earnings Date | Nov 8, 2021 |
About ARNA
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the tr...
Financial Performance
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for ARNA stock is "Strong Buy." The 12-month stock price forecast is 95.25, which is an increase of 58.54% from the latest price.
News
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ARNA--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Compensation Committee of its Board of Directors granted to 20 new employees inducem...
7 Busted Biotech Stocks Due for a Rebound
Buying biotech stocks while they're down is rewarding once they post positive clinical results, setting the stage for a big rally. The post 7 Busted Biotech Stocks Due for a Rebound appeared first on In...
Arena Pharmaceuticals to Host Virtual R&D Investor Calls and Participate in Upcoming September Investor Conferences
PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ARNA--Arena to host two virtual R&D Investor calls for analysts and investors focused on etrasimod programs in gastroenterology and dermatology.
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PARK CITY, Utah--(BUSINESS WIRE)--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Compensation Committee of its Board of Directors granted inducement stock options, inducement perfor...
Arena Pharmaceuticals, Inc. (ARNA) Reports Q2 Loss, Lags Revenue Estimates
Arena Pharmaceuticals, Inc. (ARNA) delivered earnings and revenue surprises of -8.60% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the st...
Arena Reports Second Quarter Financial Results and Key Program Updates
PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ARNA--Arena Pharmaceuticals (Nasdaq: ARNA) today provided a corporate update and reported financial results for the second quarter ended June 30, 2021.
Second Genome Announces Collaboration with Arena Pharmaceuticals to Identify Gastrointestinal Biomarkers
BRISBANE, Calif., Aug. 5, 2021 /PRNewswire/ -- Second Genome, a biotechnology company that leverages its proprietary platform sg-4-sight to discover and develop precision therapies and biomarkers from p...
Arena Pharmaceuticals to Release Second Quarter 2021 Financial Results and Provide Corporate Update on August 5
PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ARNA--Arena will release second quarter 2021 financial results and provide a corporate update on August 5, after the close of the U.S. financial markets.
Arena Pharmaceuticals and Aristea Therapeutics Establish Collaboration for Development of RIST4721 for Treatment of S...
PARK CITY, Utah, & SAN DIEGO--(BUSINESS WIRE)---- $ARNA #ARNA--Strategic collaboration and option agreement provides Arena with exclusive option to acquire Aristea and its CXCR2 programs post-Phase 2.
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ARNA--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on July 16, 2021, the Compensation Committee of its Board of Directors granted to 17 new...
Arena Pharmaceuticals Appoints Doug Manion, M.D., F.R.C.P. (C), as Executive Vice President of Research & Development
PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ARNA--Arena Pharmaceuticals announces the appointment of Douglas J. Manion, M.D., F.R.C.P. (C), as EVP of Research & Development.
Pot Stocks in Focus: Cannabis-Based Pharmaceutical Trials
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead to how the cannabis industry continues t...
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ARNA--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on June 15, 2021, the Compensation Committee of its Board of Directors granted to 17 new...
Breaking Down a Wild Week in the World of Weed Stocks
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead to how the cannabis industry continues t...
Steven Schoch Elected to Arena Pharmaceuticals Board of Directors
PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ARNA--Steven Schoch, CFO of 23andMe, appointed to Arena Pharmaceuticals' Board of Directors and as Chair of the Audit Committee.
Smoked! How the Hottest Cannabis Stocks Fared This Week
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead to how the cannabis industry continues t...
Arena's (ARNA) Etrasimod Gets FDA's Orphan Drug Tag for EoE
The FDA bestows an Orphan Drug status to Arena's (ARNA) lead pipeline candidate, etrasimod, for the treatment of eosinophilic esophagitis.
Arena (ARNA) Starts Phase II Study on Coronary Drug Temanogrel
Arena (ARNA) is developing temanogrel in a phase II study as potential treatment for coronary microvascular obstruction in patients undergoing percutaneous coronary intervention.
Arena Pharmaceuticals Announces Orphan Drug Designation for Etrasimod for the Treatment of Eosinophilic Esophagitis (...
PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation status to etra...
Arena Pharmaceuticals Announces First Participant Randomized in Phase 2 Trial Evaluating Temanogrel in Coronary Micro...
PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ARNA--Arena announces first participant randomized in Phase 2 trial evaluating IV temanogrel for the potential treatment of cMVO in patients undergoing PCI.
Why Is Arena Pharmaceuticals, Inc. (ARNA) Down 2.8% Since Last Earnings Report?
Arena Pharmaceuticals, Inc. (ARNA) reported earnings 30 days ago. What's next for the stock?
Breaking Down a Busy Week of Weed Stocks
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead to how the cannabis industry continues t...
Arena Pharmaceuticals Earns "A" Rating from MSCI ESG, a Leading Rating Agency for Sustainable Investments
PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ARNA--Arena Pharmaceuticals today announced that as of 2021, Arena received an MSCI ESG Rating of "A."
6 Cannabis Stocks Lighting Up the News This Week
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead to how the cannabis industry continues t...
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ARNA--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on May 15, 2021, the Compensation Committee of its Board of Directors granted to 22 new ...